Original document(18 pages) Authorized document(18 pages) 中文版
    The present invention relates to a pure traditional Chinese medicine for treating hepatitis B and its preparation method. The effective component of said medicine is taken from cyclene ether-terpene glycoside compound of Chinese medicinal herb rhizome picrorhizae and its main componentis rhizoma picrorhizae glycoside II. The present invention also provides freeze-dried powder for injection.
Application Number
申请号		 00135762 Application Date
申请日		 2000.12.19
Title 名称 Chinese medicine for treating hepatitis B and its preparing process
Publication Number
公开号		 1298705 Publication Date
公开日		 2001.06.13
Approval Pub. Date Granted Pub. Date 2004.03.10
International Classification 分类号 A61K9/19,A61K31/7028,A61K35/78,A61P1/16
Applicant(s) Name
申请人		 Liyuan Pharmaceutical Co Ltd, Jilin Prov.
Address 地址 133700
Inventor(s) Name 发明人 Zhou Yawei, Meng Fanlin
Attorney & Agent 代理人 huang jian

  
Preserved wet noodles producing technology
Plaster for treating hepatitis B, and its preparing method
Clathrate containing barrenwort total flavone cyclodextrin or cyclodextrin derivative, preparation and preparing method thereof
Traditional Chinese medicinal prepns. for treating osteoporosis
Antineoplastic Chinese traditional compound and the preparation and the method for producing the same
Chinese traditional medicine injection for treating HBV and the preparing method
Injection for treating hepatitis and its preparing process
Medicinal composition for treating osteoporosis and its preparations and application
Traditional Chinese medicinal composition for treating coronary heart disease and its preparation method, preparations and its application
Traditional Chinese medicinal composition for treating hepatitis and its preparation method and medicinal preparation
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.